|
Patient Characteristics
|
Total Cohort (N = 35)
|
Pazopanib-induced HTN (N = 20)
|
No Pazopanib-induced HTN (N = 15)
|
P-value
|
|---|
|
Male Gender
|
20 (57)
|
12 (60)
|
8 (53)
|
0.697
|
|
Age, years
|
61.9 ± 9.1
|
62.8 ± 10.4
|
60.7 ± 7.2
|
0.479
|
|
Pazopanib Therapy
|
|
Initial dose 800 mg QD
|
32 (91)
|
18 (90)
|
14 (93)
|
1
|
|
Initial dose 400 mg QD
|
3 (9)
|
2 (10)
|
1 (7)
|
1
|
|
Dose reduction
|
6 (17)
|
6 (30)
|
0 (0)
|
0.027
|
|
Tumor Histology
|
|
Clear cell
|
28 (80)
|
17 (85)
|
11 (73)
|
0.693
|
|
Papillary
|
4 (11)
|
2 (10)
|
2 (13)
|
0.712
|
|
Poorly differentiated
|
3 (9)
|
1 (5)
|
2 (13)
|
0.849
|
|
ECOG PS
|
|
0
|
8 (23)
|
7 (35)
|
1 (7)
|
0.101
|
|
1
|
19 (54)
|
10 (50)
|
9 (60)
|
0.734
|
|
≥2
|
8 (23)
|
3 (15)
|
5 (33)
|
0.246
|
|
Nephrectomy
|
22 (63)
|
12 (60)
|
10 (67)
|
0.687
|
|
Heart Failure
|
2 (6)
|
1 (5)
|
1 (7)
|
1
|
|
LV Dysfunction
|
7 (20)
|
2 (10)
|
5 (33)
|
0.112
|
|
Diabetes Mellitus
|
15 (43)
|
9 (45)
|
6 (40)
|
0.775
|
|
Hypertension
|
21 (60)
|
14 (70)
|
7 (47)
|
0.173
|
|
Systolic BP, mm Hg
|
126.9 ± 10.8
|
130.5 ± 10.9
|
121.7 ± 8.2
|
0.010
|
|
Diastolic BP, mm Hg
|
72.3 ± 7.4
|
74.4 ± 8.5
|
69.7 ± 4.4
|
0.045
|
|
Dyslipidemia
|
17 (49)
|
10 (50)
|
7 (47)
|
0.851
|
|
GFR < 60 mL/min/1.73 m2
|
20 (57)
|
11 (55)
|
9 (60)
|
0.767
|
|
CAD/PAD
|
5 (14)
|
2 (10)
|
3 (20)
|
0.631
|
|
CVA/TIA
|
3 (9)
|
3 (15)
|
0 (0)
|
0.244
|
|
Thromboembolism
|
7 (20)
|
3 (15)
|
4 (27)
|
0.430
|
|
Smoker
|
21 (60)
|
14 (70)
|
7 (47)
|
0.297
|
|
BMI, kg/m2
|
29.4 ± 8.7
|
28.8 ± 6.8
|
30.2 ± 11.0
|
0.680
|
|
ACEIs/ARBs
|
14 (40)
|
11 (55)
|
3 (20)
|
0.046
|
|
Beta Blockers
|
11 (31)
|
5 (25)
|
6 (40)
|
0.467
|
|
Diuretics
|
7 (20)
|
5 (25)
|
2 (13)
|
0.672
|
|
CCBs
|
9 (26)
|
7 (35)
|
2 (13)
|
0.244
|
|
Statin
|
13 (37)
|
8 (40)
|
5 (33)
|
0.737
|
|
Deceased
|
15 (43)
|
9 (45)
|
6 (40)
|
0.767
|
|
Follow-up time, months
|
10.0 [3.1-19.4]
|
11.7 [4.2-20.9]
|
6.9 [2.1-17.7]
|
0.257
|
-
HTN hypertension, QD once daily, ECOG Eastern Cooperative Oncology Group performance status, LV left ventricular, BP blood pressure, GFR glomerular filtration rate, CAD/PAD coronary artery disease/peripheral arterial disease, CVA/TIA cerebrovascular accident/transient ischemic attack, BMI body mass index, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCBs calcium channel blocker. Data presented as a number with percent (%), mean ± standard deviation, or median [1st quartile-3rd quartile]
